Pharma Industrial India’s Post

📣 New guidance for NHS–Industry Partnerships has been launched today by The Association of the British Pharmaceutical Industry (ABPI) and NHS Confederation today at #NHSConfedExpo. The potential for greater partnership is enormous - particularly in primary care - and analysis shared by Will Browne from CF shows these programmes do improve patient outcomes and efficiency of care. This new guidance aims to give greater clarity and confidence in how to create more NHS–Industry partnerships so more can benefit. https://lnkd.in/e-AzW4CH

Biosimilars: The $36 Billion Healthcare Revolution Waiting to Break Through Since the first biosimilar launch in 2015, we've witnessed a remarkable $36 billion in savings for patients and the healthcare system. Yet, we're only scratching the surface of their potential. The hidden roadblock? Pharmacy Benefit Managers (PBMs) and their complex rebate systems. These practices create a maze that favors high-priced brand biologics, effectively putting up barriers to biosimilar adoption. Our Co-founder cuts to the core of the challenge: The high development costs and extensive testing requirements are bottlenecking innovation. The Biosimilars Council could focus on streamlining approval processes, not just highlighting savings. https://lnkd.in/e9xGNTfW Key Insights: $36 billion in savings since 2015 PBM practices undermining biosimilar potential Regulatory hurdles limiting molecule approvals Urgent need for regulatory reform The future of affordable healthcare is waiting. It's time to break down the barriers and unleash the full potential of biosimilars. #Biosimilars #HealthcareSavings #GRxBiosimsSavingsReport

New guidance for NHS-Industry Partnerships- clarity and confidence paving the way for more life enhancing partnerships and the triple win for patients, the NHS and industry

Healthcare Needs Drive PHARMAC’s Transparent Funding Decisions and Strategic Prioritization The PHARMAC, New Zealand's national pharmaceutical management body, balances healthcare needs and economic factors to make strategic funding decisions. Their prioritization process is transparent, as shown in the Pūahoaho Report, which details how applications for funding medicines, vaccines, and other health products are assessed. PHARMAC collaborates with various stakeholders, including healthcare professionals and consumer groups, to ensure funding aligns with the country's healthcare needs. The agency reviews over 100 applications annually, categorized into priority lists, ensuring resources are allocated effectively based on health benefits and economic viability. For more details please click the link! https://lnkd.in/dPtGV4JT #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

The landscape of biosimilars presents significant opportunities for enhancing healthcare accessibility and affordability. This comprehensive article explores strategic approaches for effective market access, highlighting the importance of regulatory pathways, stakeholder engagement, and innovative pricing models. It details key strategies like aligning with regulations, building trust with healthcare providers and payers, and using competitive pricing to drive adoption, supported by case studies and real-world examples demonstrating successful market entry and positive patient outcomes. Source: biotechblog.com ------------------- Instituto Butantan , Instituto MECHNIKOV, S.A. , Biovac , Gennecs Pharmaceuticals , Panacea Biotec , SPBNIIVS , Techinvention Lifecare Pvt. Ltd. , Zydus Group , Sinopharm , Incepta Pharmaceuticals Ltd., Biosimilars Council, Biosimilars Forum ------------------- Access information below...

Last Chance To Register! Join us tomorrow at the 10th RWE, Market Access, Pricing & Reimbursement Global Congress 2024 Europe, taking place in London, UK on the 23rd - 24th May 2024. Event Website: www.marketaccesseurope.com For more information or to register early. info@paradigmglobalevents.com danna@paradigmglobalevents.com #MarketAccess #Reimbursemnet #patientoutcomes #drugpricing #healtheconomics #outcomesresearch #payerrelations #evidence #regulatoryaffairs #valuestrategy #patientaccess #realworlddata #clinicaltrials #clinicalresearch #clinicaldevelopment #dataanalytics #pharmaceuticals #biotechnology #rwe #marketaccess #pricingandreimbursement #healtheconomics #outcomesresearch #datamanagement #patientoutcomes #earlydevelopment #pricingstrategy #pricing #reimbursement #datamanagement #realworldevidence

🌍 The global reach of pharma companies is under the microscope! 📊 A new report highlights how leading pharmaceutical companies are addressing patient access, especially in low- and middle-income countries (LMICs). Discover the strides made, gaps that remain, and how industry leaders are tackling healthcare inequities. #Pharma #Healthcare #PatientAccess #GlobalHealth https://lnkd.in/ecfVcXNr

When I shared with my team the news from Boehringer Ingelheim earlier this month about caps on inhaler prices, I also said it's only a matter of time until we see more follow suit! This week AstraZeneca jumped into the fun! This is all playing out just like we saw with insulin in the past year What do we know: ➡ Both BI and AZ will cap out of pocket inhaler costs at $35 starting 6/1/24. ➡ We don't have details on the how yet. Anticipating the caps will leverage co-pay assistance cards like they did for insulin. ➡ Much like insulin, decrease in list prices at a later date (1/1/25) are also coming most likely due to AMP cap removal These announcements are great, but many are left out until we can get GSK (big player here), Teva, and Merck on board too! https://lnkd.in/gKbtuKTe #pharmacybenefits #pharmacists #asthma #copd #inhalers #costcap #savings

Must read! Thank you for descibing the shared ambition so on point, Amber Nigam. "...transition is toward a health ecosystem that not only values breakthroughs in medical science but also prioritizes making these innovations accessible and affordable. The concerted efforts of stakeholders, including pharmaceutical companies, healthcare providers, payers and policymakers, are crucial in navigating this landscape. By working together, these entities can establish a framework where access to essential medications becomes a cornerstone of patient care, supported by policies and practices that ensure treatments are both effective and economically viable." https://lnkd.in/ewGzmxEC IQVIA IQVIA Nederland

Last Chance To Register! Join us tomorrow at the 10th RWE, Market Access, Pricing & Reimbursement Global Congress 2024 Europe, taking place in London, UK on the 23rd - 24th May 2024. Event Website: www.marketaccesseurope.com For more information or to register early. info@paradigmglobalevents.com rizza@paradigmglobalevents.com #MarketAccess #Reimbursemnet #patientoutcomes #drugpricing #healtheconomics #outcomesresearch #payerrelations #evidence #regulatoryaffairs #valuestrategy #patientaccess #realworlddata #clinicaltrials #clinicalresearch #clinicaldevelopment #dataanalytics #pharmaceuticals #biotechnology #rwe #marketaccess #pricingandreimbursement #healtheconomics #outcomesresearch #datamanagement #patientoutcomes #earlydevelopment #pricingstrategy #pricing #reimbursement #datamanagement #realworldevidence